Desmoid fibromatosis: is the current picture changing?
Administration, Metronomic
Adolescent
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Biopsy
/ standards
Clinical Trials as Topic
DNA Mutational Analysis
Dose Fractionation, Radiation
Fibromatosis, Aggressive
/ diagnosis
Humans
Knee
/ diagnostic imaging
Magnetic Resonance Imaging
Male
Medical Oncology
/ methods
Mutation
Practice Guidelines as Topic
Prognosis
Progression-Free Survival
Watchful Waiting
/ standards
Young Adult
beta Catenin
/ genetics
active
desmoid
fibromatosis
management
medical
novel
radiation
sporadic
surgery
surveillance
targeted
Journal
Future oncology (London, England)
ISSN: 1744-8301
Titre abrégé: Future Oncol
Pays: England
ID NLM: 101256629
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
pubmed:
7
7
2021
medline:
18
1
2022
entrez:
6
7
2021
Statut:
ppublish
Résumé
Desmoid fibromatosis is a locally aggressive tumor with an unpredictable clinical course. Surgery was once the mainstay of treatment, but the treatment protocol has been constantly evolving and currently active surveillance is the front-line approach. There have been significant insights into the molecular biology with the addition of mutational analysis of Lay abstract Desmoid fibromatosis is an aggressive local tumor with continuously changing treatment paradigms. It requires MRI with biopsy for diagnosis and follow-up. Usually the tumor responds to a ‘wait and watch’ approach in most patients with either stable disease or regression on follow-up; a surgical plan is made only after multidisciplinary discussion, as surgery does not provide additional benefit in most patients. After a period of wait and watch, if there is disease progression, patients can be kept on medical management such as chemotherapy. Currently we have novel drugs for medical management like tyrosine kinase inhibitors, which result in disease stabilization in a majority of patients. In order to reduce the morbidity of treatment, it is essential for the patient to be on continuous follow-up and for clinicians to be updated with the continuously changing management of this disease.
Autres résumés
Type: plain-language-summary
(eng)
Lay abstract Desmoid fibromatosis is an aggressive local tumor with continuously changing treatment paradigms. It requires MRI with biopsy for diagnosis and follow-up. Usually the tumor responds to a ‘wait and watch’ approach in most patients with either stable disease or regression on follow-up; a surgical plan is made only after multidisciplinary discussion, as surgery does not provide additional benefit in most patients. After a period of wait and watch, if there is disease progression, patients can be kept on medical management such as chemotherapy. Currently we have novel drugs for medical management like tyrosine kinase inhibitors, which result in disease stabilization in a majority of patients. In order to reduce the morbidity of treatment, it is essential for the patient to be on continuous follow-up and for clinicians to be updated with the continuously changing management of this disease.
Identifiants
pubmed: 34227399
doi: 10.2217/fon-2021-0003
doi:
Substances chimiques
CTNNB1 protein, human
0
beta Catenin
0
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM